

**Mo-99 2015 TOPICAL MEETING ON
MOLYBDENUM-99 TECHNOLOGICAL DEVELOPMENT**

**AUGUST 31-SEPTEMBER 3, 2015
HILTON BOSTON BACK BAY
BOSTON, MASSACHUSETTS**

**Niowave's Domestic Production of Mo-99 from
Uranium to Start in 2015**

Terry L. Grimm, Stephen S. Barnard, Chase H. Boulware, Amanda K. Grimm,
Jerry L. Hollister, Mayir Mamtamin, and Valeriia N. Starovoitova
Niowave, Inc., 1012 N. Walnut St., Lansing, MI 48906 – USA

ABSTRACT

The lack of a domestic supply of Mo-99 and the current practice of using weapons grade uranium to produce Mo-99 led Congress to pass the American Medical Isotope Production Act in 2013. This legislation establishes a program to develop domestic production of Mo-99 by non-federal entities, and to phase out the use of highly enriched uranium for Mo-99 production. In March 2015 the Nuclear Regulatory Commission approved Niowave's license to produce Mo-99 from low enriched uranium using a superconducting electron linac. The first domestic production of small quantities of Mo-99 will occur toward the end of 2015. Large scale production and distribution of Mo-99 will follow in 2016-17. Chemical processing of the uranium targets will produce Mo-99 of the same quality as the existing supply chain, allowing a smooth transition to a domestic source.